NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis $15.52 +0.19 (+1.24%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$15.19▼$15.8250-Day Range$11.43▼$16.5452-Week Range$8.08▼$20.04Volume92,016 shsAverage Volume195,541 shsMarket Capitalization$328.71 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Enanta Pharmaceuticals alerts: Email Address Enanta Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside22.4% Upside$19.00 Price TargetShort InterestBearish14.78% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$246,181 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.95) to ($4.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.41 out of 5 starsMedical Sector312th out of 936 stocksPharmaceutical Preparations Industry146th out of 436 stocks 2.1 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Enanta Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.78% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 16.6, which indicates bearish sentiment.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently decreased by 3.32%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 73.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.11. Previous Next 2.7 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $246,181.00 in company stock.Percentage Held by Insiders13.64% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enanta Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($5.95) to ($4.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -2.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Enanta Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Read More ENTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTA Stock News HeadlinesJuly 16, 2024 | insidertrades.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Scott T. Rottinghaus Sells 5,375 SharesJuly 16, 2024 | insidertrades.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Insider Sells $64,785.93 in StockJuly 27, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.May 29, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at the Jefferies Global Healthcare ConferenceMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: Enanta Pharmaceuticals’ Clinical and Financial Prospects Bolster Investor ConfidenceMay 8, 2024 | finance.yahoo.comEnanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | markets.businessinsider.comHold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial OutlookMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial ExecutionJuly 27, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call TranscriptMay 7, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at the JMP Securities Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ...May 7, 2024 | chron.comEnanta Pharmaceuticals: Fiscal Q2 Earnings SnapshotMay 6, 2024 | finance.yahoo.comEnanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst ExpectationsMay 6, 2024 | businesswire.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ETMay 5, 2024 | msn.comEnanta Pharma Q2 2024 Earnings PreviewMay 5, 2024 | markets.businessinsider.comEnanta Pharmaceuticals is about to announce its earnings — here's what to expectMay 3, 2024 | finance.yahoo.comStrong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year lossSee More Headlines Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees160Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$27.00 Low Stock Price Target$11.00 Potential Upside/Downside+22.4%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-133,820,000.00 Net Margins-180.76% Pretax Margin-178.25% Return on Equity-64.85% Return on Assets-29.28% Debt Debt-to-Equity RatioN/A Current Ratio6.43 Quick Ratio6.43 Sales & Book Value Annual Sales$79.20 million Price / Sales4.15 Cash FlowN/A Price / Cash FlowN/A Book Value$10.29 per share Price / Book1.51Miscellaneous Outstanding Shares21,180,000Free Float18,290,000Market Cap$328.71 million OptionableOptionable Beta0.60 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Jay R. Luly Ph.D. (Age 68)President, CEO & Director Comp: $1.25MMr. Paul J. Mellett Jr. (Age 69)Senior VP of Finance & Administration and CFO Comp: $666.84kDr. Yat Sun Or Ph.D. (Age 72)Senior VP of Research & Development and Chief Scientific Officer Comp: $729.31kMr. Nathaniel S. Gardiner J.D. (Age 70)Consultant Comp: $672.67kMr. Brendan Luu (Age 49)Senior Vice President of Business Development Comp: $622.86kMs. Jennifer VieraSenior Director of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsGenfitNASDAQ:GNFTProthenaNASDAQ:PRTAArdelyxNASDAQ:ARDXOcular TherapeutixNASDAQ:OCULGyre TherapeuticsNASDAQ:GYREView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 8,645 shares on 7/26/2024Ownership: 0.349%Allspring Global Investments Holdings LLCBought 2,667 shares on 7/26/2024Ownership: 0.013%Assenagon Asset Management S.A.Sold 157,097 shares on 7/18/2024Ownership: 2.014%Scott T RottinghausSold 5,375 sharesTotal: $91,805.00 ($17.08/share)Scott T RottinghausSold 4,299 sharesTotal: $64,785.93 ($15.07/share)View All Insider TransactionsView All Institutional Transactions ENTA Stock Analysis - Frequently Asked Questions How have ENTA shares performed this year? Enanta Pharmaceuticals' stock was trading at $9.41 at the beginning of the year. Since then, ENTA shares have increased by 64.9% and is now trading at $15.52. View the best growth stocks for 2024 here. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings data on Monday, May, 6th. The biotechnology company reported ($1.47) EPS for the quarter, missing analysts' consensus estimates of ($1.26) by $0.21. The biotechnology company had revenue of $17.05 million for the quarter, compared to analyst estimates of $16.47 million. Enanta Pharmaceuticals had a negative net margin of 180.76% and a negative trailing twelve-month return on equity of 64.85%. What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend. Who are Enanta Pharmaceuticals' major shareholders? Top institutional investors of Enanta Pharmaceuticals include Assenagon Asset Management S.A. (2.01%), Bank of New York Mellon Corp (0.35%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Jay R Luly, Yat Sun Or, Paul J Mellett, Brendan Luu, Nathalie Adda, Tara Lynn Kieffer, Scott T Rottinghaus and Terry Vance. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA) and Netflix (NFLX). This page (NASDAQ:ENTA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
